Rhythm Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: RYTM · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1649904
| Field | Detail |
|---|---|
| Company | Rhythm Pharmaceuticals, Inc. (RYTM) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing-update
Related Tickers: RYTM
TL;DR
RHYTHM PHARMACEUTICALS (RYTM) filed an 8-K on Sep 18th regarding shareholder votes. No major financial news, but check for governance updates.
AI Summary
Rhythm Pharmaceuticals, Inc. filed an 8-K on September 19, 2024, reporting on matters submitted to a vote of security holders on September 18, 2024. The filing details the company's corporate structure and operational information, including its principal executive offices in Boston, MA.
Why It Matters
This filing provides an update on corporate governance and shareholder decisions, which can impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is procedural and reports on matters already voted on by shareholders, without disclosing new financial risks or significant operational changes.
Key Players & Entities
- RHYTHM PHARMACEUTICALS, INC. (company) — Registrant
- September 18, 2024 (date) — Date of earliest event reported
- September 19, 2024 (date) — Filing date
- Boston, MA (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders on September 18, 2024?
The filing indicates that matters were submitted to a vote of security holders on September 18, 2024, but the specific details of these matters are not provided in the excerpt.
What is the principal executive office address for Rhythm Pharmaceuticals, Inc.?
The principal executive offices are located at 222 Berkeley Street, 12th Floor, Boston, MA 02116.
When was Rhythm Pharmaceuticals, Inc. incorporated?
The company was incorporated in Delaware.
What is the IRS Employer Identification Number for Rhythm Pharmaceuticals, Inc.?
The IRS Employer Identification Number is 46-2159271.
What is the SIC code for Rhythm Pharmaceuticals, Inc.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 730 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-19 16:49:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share RYTM The Nasdaq
- $1,000 — l to 20.8333 shares of common stock per $1,000 liquidation preference of Series A conv
Filing Documents
- tm2424430d1_8k.htm (8-K) — 29KB
- 0001104659-24-101393.txt ( ) — 199KB
- rytm-20240918.xsd (EX-101.SCH) — 3KB
- rytm-20240918_lab.xml (EX-101.LAB) — 33KB
- rytm-20240918_pre.xml (EX-101.PRE) — 22KB
- tm2424430d1_8k_htm.xml (XML) — 4KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 18, 2024 Rhythm Pharmaceuticals, Inc. (the "Company") held its Annual Meeting of Stockholders. At the close of business on the July 24, 2024 record date (the "Record Date"), there were (i) 61,130,640 shares of the Company's common stock outstanding, of which each share of common stock was entitled to one vote; and (ii) 150,000 shares of the Company's Series A convertible preferred stock ("Convertible Preferred Stock") outstanding, of which 90,000 shares were entitled to vote (each share of Convertible Preferred Stock being entitled to a number of votes equal to 20.8333 shares of common stock per $1,000 liquidation preference of Series A convertible preferred stock). As a result, there were a total of 63,005,638 eligible votes as of the record date. A total of 53,945,997 votes were present online or represented by proxy at the meeting, representing approximately 85.6% of the total eligible votes as of the Record Date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's amended and restated definitive proxy statement filed with the Securities and Exchange Commission on August 7, 2024.
- Election of three Class I Directors to
Item 1 - Election of three Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Stuart A. Arbuckle 45,585,464 6,530,701 1,829,832 Christophe R. Jean 45,017,705 7,098,460 1,829,832 Lynn A. Tetrault 45,485,067 6,631,098 1,829,832
- Ratification of the appointment of Ernst
Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 53,844,430 69,539 32,028 0
- Approval, on an advisory (non-binding)
Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 50,612,289 1,487,317 16,559 1,829,832
- Reapproval of the Rhythm Pharmaceuticals,
Item 4 - Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 32,739,796 19,359,379 16,990 1,829,832 Based on the foregoing votes, Stuart A. Arbuckle, Christophe R. Jean, and Lynn A. Tetrault were elected as Class I Directors, and Items 2, 3 and 4 were approved.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHYTHM PHARMACEUTICALS, INC. Date: September 19, 2024 By: /s/ Hunter Smith Hunter Smith Chief Financial Officer